Incidence of Laboratory Tumor Lysis Syndrome in CAR T-Cell Recipients

Tumor lysis syndrome (TLS) is a complication commonly seen in hematological malignancies after patients receive antineoplastics due to the rapid release of cell contents including potassium, phosphorus, and the breakdown of nucleic acids to produce high levels of uric acid. Despite landmark chimeric antigen receptor (CAR) T-cell trials reporting TLS to be an uncommon adverse event, there is a lack of consensus on utilizing prophylactic allopurinol as a preventative strategy. Currently, there are no randomized trials that have assessed TLS as a primary endpoint with CAR T-cell recipients.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 632 Source Type: research